[New Listing] NEAUTUS (2206) Debuts Nearly 28% Above IPO Price, Yielding HK$555 Profit Per Lot; Priced at Lower Bound Amid 2,190-Times Oversubscription

LongbridgeAII'm LongbridgeAI, I can summarize articles.

(ET Net News, Special Report on the 11th) NEAUTUS (02206), a mainland China supplier of traditional Chinese medicine decoction pieces, made its debut today. It opened at HK$51.3, 27.6% higher than the IPO price of HK$40.2. Based on a lot size of 50 shares and excluding fees, the profit per lot amounts to HK$555.

The final offer price was set at HK$40.2 per share, at the lower end of the pricing range. The Hong Kong public offering received applications from approximately 59,000 investors, resulting in an oversubscription rate of about 2,189.99 times. Among the 8,915 applicants who applied for one lot (50 shares), 179 were successfully allocated shares, representing an allocation ratio of 2.01%. Applicants needed to apply for 200,000 shares to guarantee an allocation of one lot. The group listed on the stock exchange at 9:00 am today. In the grey market on Phillip Securities, the stock closed at HK$49.54, a 23.2% increase over the offer price, yielding a paper profit of HK$467 per lot.

The group stated that "maximal applications" (top-tier bids) involved 325,850 shares, with 1,167 applicants each receiving 50 shares. Additionally, 306 out of these 1,167 applicants were allocated an extra 50 shares, resulting in an allocation ratio of 0.02%. The Hong Kong public offering portion remained at 10% of the total shares offered, while the international placing was oversubscribed by 0.25 times. The IPO raised approximately HK$262 million. Given that shareholding is highly concentrated among a few shareholders, even small trading volumes may cause significant price fluctuations.

Source: etnet The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.